Mereo BioPharma Group (LON:MPH) Posts Quarterly Earnings Results, Misses Expectations By $11.50 EPS

Mereo BioPharma Group (LON:MPH) announced its earnings results on Tuesday. The company reported GBX (39) (($0.50)) earnings per share (EPS) for the quarter, missing the consensus estimate of GBX (27.50) (($0.35)) by GBX (11.50) (($0.15)), Digital Look Earnings reports.

LON:MPH traded up GBX 1 ($0.01) during midday trading on Tuesday, reaching GBX 40.50 ($0.52). 174,313 shares of the stock traded hands, compared to its average volume of 266. Mereo BioPharma Group has a 12-month low of GBX 13 ($0.17) and a 12-month high of GBX 75 ($0.95). The business has a 50-day moving average of GBX 24.48 and a two-hundred day moving average of GBX 27.01. The company has a debt-to-equity ratio of 55.68, a quick ratio of 2.18 and a current ratio of 2.32. The stock has a market capitalization of $22.16 million and a PE ratio of -0.95.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease.

Further Reading: Total Return

Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with's FREE daily email newsletter.